Titan Biotech Limited (BOM:524717)

Titan Biotech Balance Sheet

Financials in millions INR. Fiscal year is April - March.

Assets

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Cash & Equivalents	-	18.73	55.58	32.86	48.64	68.14
Cash & Short-Term Investments	18.73	18.73	55.58	32.86	48.64	68.14
Cash Growth	-66.30%	-66.30%	69.18%	-32.45%	-28.62%	25.01%
Accounts Receivable	-	228.29	188.16	186.58	210.08	163.59
Receivables	-	228.29	188.16	186.58	210.08	163.59
Inventory	-	557.69	507.23	455.71	361.7	346.8
Prepaid Expenses	-	-	3.17	1.87	1.23	-
Other Current Assets	-	47.72	36.23	49.18	61.42	59.03
Total Current Assets	-	852.43	790.38	726.2	683.06	637.56
Property, Plant & Equipment	-	632.52	588.46	544.7	491.04	385.15
Long-Term Investments	-	603.63	347.91	285.48	156.69	40.31
Other Intangible Assets	-	0.84	1.22	0.95	0.85	1.05
Other Long-Term Assets	-	49.44	19.11	12.93	13.52	16.85
Total Assets	-	2,139	1,747	1,570	1,345	1,081

Liabilities

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Accounts Payable	-	85.41	52.17	33.68	55.5	41.6
Accrued Expenses	-	8.69	72.46	66.46	55.51	39.37
Short-Term Debt	-	33.44	19.18	67.18	67	64.5
Current Portion of Leases	-	5.93	8.9	8.83	3.81	2.9
Current Income Taxes Payable	-	12.66	-	-	0.29	3.14
Other Current Liabilities	-	113.5	24.66	19.56	21.41	17.99
Total Current Liabilities	-	259.63	177.36	195.71	203.51	169.49
Long-Term Debt	-	3.27	1.84	4.53	2.99	10.81
Long-Term Leases	-	14.43	2.35	6.94	11.32	11.09
Pension & Post-Retirement Benefits	-	22.79	16.28	14.83	16.15	14.33
Long-Term Deferred Tax Liabilities	-	23.26	15.21	13.72	12.07	12.76
Total Liabilities	-	323.37	213.04	235.74	246.04	218.47

Shareholders' Equity

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Common Stock	-	82.64	82.64	82.64	82.64	82.64
Additional Paid-In Capital	-	-	86.75	86.75	86.75	86.75
Retained Earnings	-	-	1,361	1,162	928.21	692.17
Comprehensive Income & Other	-	1,733	3.99	3.26	1.51	0.89
Total Common Equity	1,815	1,815	1,534	1,335	1,099	862.44
Shareholders' Equity	1,815	1,815	1,534	1,335	1,099	862.44
Total Liabilities & Equity	-	2,139	1,747	1,570	1,345	1,081

Additional Metrics

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Total Debt	57.07	57.07	32.27	87.48	85.12	89.3
Net Cash (Debt)	-38.34	-38.34	23.31	-54.63	-36.48	-21.16
Net Cash Growth	-	-	-	-	-	-
Net Cash Per Share	-0.77	-0.93	0.56	-1.32	-0.88	-0.51
Filing Date Shares Outstanding	41.28	41.32	41.32	41.32	41.32	41.32
Total Common Shares Outstanding	41.28	41.32	41.32	41.32	41.32	41.32
Working Capital	-	592.8	613.02	530.49	479.55	468.06
Book Value Per Share	43.94	43.94	37.13	32.30	26.60	20.87
Tangible Book Value	1,815	1,815	1,533	1,334	1,098	861.4
Tangible Book Value Per Share	43.92	43.92	37.10	32.28	26.58	20.85
Buildings	-	-	218.37	207.56	130.34	130.25
Machinery	-	-	474.05	391.37	281.77	254.21
Construction In Progress	-	-	16.84	25.32	132.94	36.34

Data Source: S&P Global Market Intelligence Last updated: Jun 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 19, 2026

Data Sources Report a data error